$PBIO Pressure BioSciences Updates Forecast with Six Key Goals for June 2023 with Expected Multi-Million Dollar Growth Increments in FY 2023 and Beyond
https://www.accesswire.com/758611/Pressure-Bi...and-Beyond
SOUTH EASTON, MA / ACCESSWIRE / June 1, 2023 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBIO" or the "Company"
, a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries today highlighted the six key goals they expect to achieve during the month of June 2023, and discussed the significant financial impact expected to result for the Company in FY 2023 and beyond. The top six goals expected to be completed in June include:
1. Addition of Three $1M+ (Annual) Nano-CBD Commercial Distribution Contracts
Leading Retailer (CBD Supply MD) recently introduced NanoBloom CBD to their multi-state client base.
PBI believes the Agreement with CBD Supply MD will be worth $1.5M+ over the next 12 months.
PBI anticipates three additional CBD retailers with similar revenue potential to close during June 2023.
2. Sale of Two Licenses ($1M+) for PBI's Patented UltraShear™ Platform for Nano-THC Processing
Multiple groups are negotiating a possible purchase of a 3-year exclusive THC processing license for a state.
PBI anticipates the sale of two exclusive licenses to close during June 2023.
PBI expects most license sales to generate - on average - about $1M in up-front fees.
3. Completion of Third (and Largest) Consumer Focus Group on Nano-THC
Two focus groups have validated the market transforming speed and dosing efficiency of PBI's Nano-THC.
Third focus group expected to further validate these results, plus super-fast pain relief from topical use.
4. John Westlake, Canopy CBD Farms ("CCF" , to Launch as Master Distributor of Nano-Cannabis Products
Assumes heightened role as a master distributor of PBIO nano-cannabis products in June 2023.
John/CCF delivers multiple sales channels, a deep nationwide industry network, and access to media and capital.
5. Initial Production Runs in PBIO's New Strategic Manufacturing Facilities
PBI's severe capacity limitations in current production facilities become relieved with new expansion transition into strategic partner Artisan Industries facilities, only 6 miles from PBI headquarters.
6. Dr. Denese Skin Science Collaboration Completes First Retinol Product R&D Phase - Expects Marketing LOI
Retinol-based anti-aging creams and serums are among the Dr. Denese Skin Science top sellers on QVC.
Dr. Denese believes PBIO's UltraShear nanoemulsification technology is the enabling platform for a revolutionary new generation of skincare.
PBI has completed the development of UltraShear-processed retinol with lipid-soluble Vitamin C formulations.
PBI anticipates a formal product marketing Letter-of-Intent (LOI) on these products with Dr. Denese in June.
Mr. Richard T. Schumacher, PBIO's President and CEO stated: "We have been laser-focused on making measurable progress on those areas that offer the best potential for rapid recurring revenue growth in the near future. I am pleased to say that the PBI Team has been highly successful in these endeavors. Progress on the six goals delineated here is a testament to their hard work and effectiveness - and to the value proposition of our UltraShear platform. All told, the incremental annual revenue expected from these goals, which our team expects to complete in June, should exceed several millions of dollars during the second half of FY 2023 alone, with incremental revenues growing further in FY 2024 and beyond."
Mr. Schumacher concluded: "We have accomplished a great deal in product development, technology demonstrations, and early commercial traction over the past year - and we believe that PBIO is highly undervalued at current market prices. We are continuing to help current and future investors understand the enormous potential of our many assets, especially our revolutionary (and diversely patented) Ultra Shear nanoemulsions technology platform."
https://www.accesswire.com/758611/Pressure-Bi...and-Beyond
SOUTH EASTON, MA / ACCESSWIRE / June 1, 2023 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBIO" or the "Company" , a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries today highlighted the six key goals they expect to achieve during the month of June 2023, and discussed the significant financial impact expected to result for the Company in FY 2023 and beyond. The top six goals expected to be completed in June include: 1. Addition of Three $1M+ (Annual) Nano-CBD Commercial Distribution Contracts
Leading Retailer (CBD Supply MD) recently introduced NanoBloom CBD to their multi-state client base.
PBI believes the Agreement with CBD Supply MD will be worth $1.5M+ over the next 12 months.
PBI anticipates three additional CBD retailers with similar revenue potential to close during June 2023.
2. Sale of Two Licenses ($1M+) for PBI's Patented UltraShear™ Platform for Nano-THC Processing
Multiple groups are negotiating a possible purchase of a 3-year exclusive THC processing license for a state.
PBI anticipates the sale of two exclusive licenses to close during June 2023.
PBI expects most license sales to generate - on average - about $1M in up-front fees.
3. Completion of Third (and Largest) Consumer Focus Group on Nano-THC
Two focus groups have validated the market transforming speed and dosing efficiency of PBI's Nano-THC.
Third focus group expected to further validate these results, plus super-fast pain relief from topical use.
4. John Westlake, Canopy CBD Farms ("CCF"
, to Launch as Master Distributor of Nano-Cannabis Products Assumes heightened role as a master distributor of PBIO nano-cannabis products in June 2023.
John/CCF delivers multiple sales channels, a deep nationwide industry network, and access to media and capital.
5. Initial Production Runs in PBIO's New Strategic Manufacturing Facilities
PBI's severe capacity limitations in current production facilities become relieved with new expansion transition into strategic partner Artisan Industries facilities, only 6 miles from PBI headquarters.
6. Dr. Denese Skin Science Collaboration Completes First Retinol Product R&D Phase - Expects Marketing LOI
Retinol-based anti-aging creams and serums are among the Dr. Denese Skin Science top sellers on QVC.
Dr. Denese believes PBIO's UltraShear nanoemulsification technology is the enabling platform for a revolutionary new generation of skincare.
PBI has completed the development of UltraShear-processed retinol with lipid-soluble Vitamin C formulations.
PBI anticipates a formal product marketing Letter-of-Intent (LOI) on these products with Dr. Denese in June.
Mr. Richard T. Schumacher, PBIO's President and CEO stated: "We have been laser-focused on making measurable progress on those areas that offer the best potential for rapid recurring revenue growth in the near future. I am pleased to say that the PBI Team has been highly successful in these endeavors. Progress on the six goals delineated here is a testament to their hard work and effectiveness - and to the value proposition of our UltraShear platform. All told, the incremental annual revenue expected from these goals, which our team expects to complete in June, should exceed several millions of dollars during the second half of FY 2023 alone, with incremental revenues growing further in FY 2024 and beyond."
Mr. Schumacher concluded: "We have accomplished a great deal in product development, technology demonstrations, and early commercial traction over the past year - and we believe that PBIO is highly undervalued at current market prices. We are continuing to help current and future investors understand the enormous potential of our many assets, especially our revolutionary (and diversely patented) Ultra Shear nanoemulsions technology platform."
